Just a moment, the page is loading...

To initiate a Research Proposal or to Ask a Question about studies, please do the following:

  • Login and create an account.
  • Click on the Study ID to view Study Details.
  • If you cannot find the specific study you are looking for, click here to submit an Enquiry
×


2997 Results:


Sponsor Studies ↑ Description Ready to Share Created
 
Astellas ASTELLAS-015K-CL-PS01 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis No 3/31/2020
 
Astellas ASTELLAS-015K-CL-RA21 A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients who have had an Inadequate Response to Methotrexate No 2/18/2020
 
Astellas ASTELLAS-015K-CL-RA22 A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients No 2/18/2020
 
Astellas ASTELLAS-015K-CL-RA25 A Phase 2 Open-label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study No 2/18/2020
 
Astellas ASTELLAS-015K-CL-RAJ1 Phase 2b Study of ASP015K – A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients – No 7/14/2020
 
Astellas ASTELLAS-015K-CL-RAJ3 Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs - No 7/14/2020
 
Astellas ASTELLAS-015K-CL-RAJ4 Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX - No 7/14/2020
 
Astellas ASTELLAS-0456-CL-1021 Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) No 2/28/2020
 
Astellas ASTELLAS-0456-CL-1031 Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) - No 2/28/2020
 
Astellas ASTELLAS-1707-CL-0011 A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment No 2/18/2020